UNSPSC 51183502: Buformin

This classification denotes an anti-diabetic agent with the molecular formula C6H15N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W2115E9C7B, chemically known as imidodicarbonimidic diamide, n-butyl- but more generally known as buformin, which bears US NIH Compound Identifier 2468. Buformin most often comes in base and hydrochloride forms. European Medicines Agency schedules Buformin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05965MIG.

UNSPSC 51183502 Buformin, a Commodity code, covers generic pharmaceutical products supplied through cooperative purchasing vehicles to state and local government health systems, correctional facilities, and other public agencies. State and local governments procure buformin and related generic pharmaceuticals through multistate cooperative agreements that consolidate demand across multiple participating jurisdictions, enabling volume-based pricing and standardized supply agreements with authorized wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers the primary recent solicitation activity in this space, with participating entities spanning Minnesota, Oregon, and other states on the cooperative roster. Issuing bodies include state health departments and purchasing offices that establish master agreements on behalf of counties, cities, school districts, and special-purpose health authorities within their networks.

The Minnesota Department of Administration's Office of State Procurement, operating through MMCAP, issued a Request for Proposal (S1070000015802) on January 20, 2026 for multiple manufacturers to supply generic multi-source pharmaceuticals and over-the-counter products with a March 26, 2026 response deadline. The RFP targets vendors able to meet current Good Manufacturing Practices certification and Drug Supply Chain Security Act compliance, with products required to be available by May 15, 2026 and resulting contracts effective July 1, 2026. Vendors must establish relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), submit detailed product specifications including National Drug Codes and SKUs, and accept a 3 percent administrative fee on all contract purchases. The evaluation weights pricing competitiveness at 75 percent of the award decision, with the remaining 25 percent split among administrative compliance, EDI capability, fixed-price commitment, and fee structure. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic need and member-specific requirements; no specific dollar value or budget range was disclosed in the solicitation.